Navigation Links
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Date:5/20/2009

June 1994 to July 1998, Mr. Bentsur worked as an investment banker in NYC, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA, Magna Cum Laude, from New York University's Stern Graduate School of Business.

The terms of Mr. Bentsur's employment are being finalized and will be set forth in an employment agreement with the Company. As an inducement to his employment, the Company has granted Mr. Bentsur options to purchase 600,000 shares of Company common stock, at an exercise price equal to the fair market value of the stock as of May 20, 2009, the date of grant. The options will vest in equal annual installments over a four-year period or upon an earlier change in control of the Company.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
(Date:7/10/2014)... today in the journal PNAS (Proceedings of the ... of day and sleep deprivation have a significant effect ... looking at the best time of day to test ... for administering medicines effectively. , Researchers from the University ... investigated the links between sleep deprivation, body clock disruption ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2
... new Network222 development in downtown Madison is State Street, a ... to government conspiracies. , ,Up on the hill, the developers ... message, one of bright ideas and high-tech innovation. And theyve ... office building, already home to several companies, is a $12 ...
... also reared their heads again-- Lovegate-E and Funlove --spreading concern ... and firewalls up-to-date. , ,"It's no good installing the ... , ,A new virus called Datemake Dialler also made its ... dialer, is programmed to dial a premium-rate telephone line ...
... New York, NY - One certain consequence of the ... cleaning. The first bigwig out the door is Dr. ... and development operations. Today, Celltech, one of Europe's biggest ... , ,"You will see that the entire senior management ...
Cached Biology Technology:Wired to the Max: Network 222 2Wired to the Max: Network 222 3Wired to the Max: Network 222 4Pfizer-Pharmacia Fallout Gives Celltech A CEO 2
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
(Date:7/10/2014)... 2014  Unisys Corporation,s (NYSE: UIS ) subsidiary ... today announced that it has been selected by the Dutch ... new Basic Provision Biometrics solution for penitentiaries across ... contract with a solution based on its open standards-based ... the contract is up to seven years, with the new ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... study to identify the origin cells and track the early ... new cell source and biological roadmap for therapies to repair ... transformative therapies could reach clinical trials within three years, said ... Regenerative Medicine and Stem Cell Research. The ...
... in mice shows how a breakdown of the brain,s ... Alzheimer,s disease. The results published in Nature ... may provide novel targets for treatments and diagnoses. ... may contribute to the development of Alzheimer,s disease," said ...
... researchers from the National University of Singapore (NUS) have ... to form suspended "bridges" during wound healing. The new ... as the design of artificial skin, and better wound ... the Mechanobiology Institute (MBI) at NUS and Departments of ...
Cached Biology News:UCLA stem cell scientists first to track joint cartilage development in humans 2UCLA stem cell scientists first to track joint cartilage development in humans 3Study breaks blood-brain barriers to understanding Alzheimer's 2Study breaks blood-brain barriers to understanding Alzheimer's 3New discovery on how skin cells form 'bridges' paves the way for advances in wound healing 2
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
Biology Products: